Global Peptide Drug Conjugate Market Opportunity Clinical Trials Insight 2026
USA - English
News provided by
Share this article
Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights:
First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)
Pepaxto Clinical and Commercial Insight: Dosage, Patent, Price, Sales Forecast
Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan and South Korea
Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs
Clinical Trials Insight by Company, Country, Indication
Patent Insight of Peptide Drug Conjugates
Profile and Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 provides comprehensive insight on clinical and non clinical factors that are driving the peptide drug conjugate market and its impact on the global pharmaceutical market landscape. The report has been prepared in a vi
Cybrexa Therapeutics Closes $25 Million Series B Financing
-Proceeds will advance the company s lead program into clinical trials-
NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Street Ventures. Proceeds from the financing will be used to support the planned advancement of Cybrexa s lead candidate CBX-12 (alphalex-exatecan) into the clinic. The first patient dosing in the Phase 1 study is expected in the first half of 2021.
Investegate |Cybrexa Therapeutics Announcements | Cybrexa Therapeutics: Cybrexa Therapeutics Closes $25 Million Series B Financing investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
(1)
- Cybrexa and NCI to collaborate on clinical development of Cybrexa s lead candidate, CBX-12, to assess the safety and efficacy in oncology patients with solid tumors -
NEW HAVEN, Conn., Feb. 24, 2021 (GLOBE NEWSWIRE) Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has entered a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), part of the National Institutes of Health. Under terms of the agreement, Cybrexa and the NCI will collaborate on pre-clinical and potential clinical development of Cybrexa s lead therapeutic candidate, CBX-12 (alphalex-exatecan).
Cybrexa Therapeutics Reports Positive Results from GLP Toxicology Study of Lead Candidate CBX-12 (alphalex-exatecan)
- No Unexpected Safety Findings During the Course of the Study -
- On Track to File an IND in the First Quarter 2021 and Commence Phase I Trial by Mid Year 2021 -
NEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has completed the GLP toxicology study of its lead candidate, CBX-12. The positive results for this study serve as a guide for dosing regimen for the planned Phase I trial of CBX-12 as Cybrexa intends to file the IND during the first quarter 2021.